Di Castelnuovo, 3,451 patient HCQ late treatment study: 30% lower mortality [p<0.0001] https://c19p.org/dicastelnuovo
copied to clipboard
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
et al., European J. Internal Medicine, doi:10.1016/j.ejim.2020.08.019
Retrospective 3,451 hospitalized patients, 30% reduction in mortality with HCQ after propensity adjustment, HR 0.70 [0.59 - 0.84].
|
risk of death, 30.0% lower, HR 0.70, p < 0.001, treatment 386 of 2,634 (14.7%), control 90 of 817 (11.0%), adjusted per study.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Di Castelnuovo et al., 8/25/2020, retrospective, Italy, Europe, peer-reviewed, 110 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.